Supernus Up on Report of Progress With ADHD Treatment
Supernus said that a Phase 3 trial met the primary endpoint . compared to placebo in improving the symptoms of ADHD.
Author:
Supernus Pharmaceuticals (
SUPN) - Get Report shares jumped on Wednesday after the drugmaker focused on the central nervous system reported progress in a Phase 3 study of an attention-deficit-hyperactivity-disorder drug.
Supernus recently traded at $26.70, up 19%. The stock remains off 2% year to date.
“At a daily dose of up to 600mg, the trial met the primary endpoint with robust statistical significance (p=0.0040) compared to placebo in improving the symptoms of ADHD,” the company said in a statement.